Advanced Biomed Inc. has received a notice from Nasdaq indicating that the company's common stock has failed to meet the minimum bid price requirement of $1.00 per share for the past 32 consecutive business days. This notice, however, does not immediately affect the stock's listing or trading on the Nasdaq Capital Market, where it continues to trade under the symbol "ADVB." To comply with Nasdaq's Listing Rule 5550(a)(2), Advanced Biomed has until January 14, 2026, to raise its stock price to at least $1.00 for ten consecutive business days. If compliance is not achieved by this deadline, the company may qualify for an additional 180-day extension to meet listing standards, contingent on specific conditions. Advanced Biomed is actively exploring options to address this issue within the allotted timeframe.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.